Curing the Incurable

The immune system is one of the most sophisticated systems in our bodies for the diagnosis and treatment of most diseases. However, the potential of the immune system has not been fully exploited in the field of medicine to date as its mechanism of action has not been completely elucidated. Our company is developing businesses that support and promote unprecedented new medical development (basic research, prevention, diagnosis, and treatment) using the immune system in a wide range of medical applications by integrating accurate and vast information obtained from our proprietary immune diversity analysis technology.

Since its establishment in October 2014, our company has been analyzing for many diseases such as cancer, infectious diseases, and autoimmune diseases, with a particular focus on the detailed analyses of T cell receptors and B cell receptors on the surfaces of T cells and B cells, respectively, which are two major lymphocyte populations. Moreover, our company has established partnerships with a number of academic institutions and biopharmaceutical companies. In the future, we will continue cooperating with research institutions to advance research and development that contribute to human health by disseminating our unique immune diversity analysis technology to the world, with an aim to understand the immune system better and enable the realization of a world of “Curing the Incurable”.

President & CEO
Masuo Ichikawa